While younger women often report milder nosebleeds than men, a surprising trend emerges as the decades pass. Men typically see a slow, linear increase in symptoms due to cumulative nasal trauma. In contrast, women experience an accelerated worsening of symptoms that correlates with the onset of menopause.

This isn’t just a perceived change; it is measurable. Research shows that the “Epistaxis Severity Score” (ESS) increases at a rate of 0.055 points more per year in women than in men. This means that after 20 years of aging, a woman’s symptoms are estimated to be significantly more severe than her male counterparts. This suggests that oestrogen acts as a natural guardian of the nasal lining, a defence that unfortunately crumbles as hormone levels drop.

There is a persistent myth that the high hormone levels of pregnancy might naturally “soothe” HHT symptoms. However, for many women, the reality is a “Pregnancy Paradox” where the second trimester brings a sharp decline in health. Increasing blood volumes and the softening of connective tissues often combine to make fragile vessels even more prone to rupture.

Data from a major study by Droege et al. found that 39% of women saw their HHT symptoms worsen during pregnancy. This vulnerability can even extend into the “fourth trimester.” Interestingly, researchers noted a genetic nuance: women with HHT Type 1 showed a stronger tendency for their symptoms to worsen during the lactation period compared to those with HHT Type 2. As the study notes:

“Most women experienced an increase of their HHT symptoms during their pregnancy. Especially in the second trimester, half of the patients noticed changes… suffering from more bleedings and telangiectasia.”

In a fascinating “off-label” discovery, doctors have found that the combined oestrogen and progestin found in oral contraceptives can act as a physical shield. For women of reproductive age, these hormones appear to offer two distinct layers of protection. First, they induce “squamous metaplasia,” a process that thickens the nasal mucosa and creates a tougher barrier against the friction of everyday breathing.

Beyond just a physical barrier, these hormones also appear to change the “stickiness” of the blood. By exerting pro-thrombotic effects, they may help the body form more stable clots in areas where vessels are fragile. The results are life-changing for many; 52% of women using combined hormonal therapy reported a significant reduction in their chronic bleeding.

Perhaps the most compelling evidence of the hormone-HHT link came from a “medical detective” moment involving an anti-oestrogen drug. A 57-year-old woman with severe, daily nosebleeds was diagnosed with breast cancer and started on Tamoxifen. To the shock of her medical team, her chronic nosebleeds—which had resisted multiple laser surgeries—stopped almost immediately.

This created a scientific puzzle: if adding oestrogen helps some, why does a drug that blocks estrogen help others? Scientists suspect the answer lies in “fibrinolysis,” the process by which our bodies break down blood clots. Tamoxifen may work by slowing down this breakdown, allowing the body’s natural repairs to last longer. This accidental cure suggests that HHT’s relationship with the endocrine system is far more complex than we ever imagined.

In a cruel twist of medical irony, the same hormones that act as a shield for the nose can pose a serious danger to internal organs. While women may have more protection against nosebleeds in youth, they carry a much higher risk for “silent” internal malformations. This gendered risk is most evident in the liver, where the stakes are significantly higher.

• Hepatic Vascular Malformations (HVMs): These abnormal liver vessels are 2 to 4.5 times more common in females than males.
• High-Output Cardiac Failure: These liver malformations can force the heart to work overtime, potentially leading to failure.
• The Pregnancy Link: Both pregnancy and oestrogen replacement therapy are specifically linked to the progression of these dangerous liver issues.
• Clot Risks: Hormonal factors increase the risk of Budd-Chiari Syndrome, a rare condition where the veins draining the liver become blocked.

The shifting landscape of HHT research proves that this is not a “one-size-fits-all” condition. A patient’s hormonal profile—dictated by age, life stage, or medication—is a fundamental driver of their disease. By understanding these “hidden switches,” doctors can move toward more personalized, empathetic care that addresses the whole person, not just the symptom.

If hormones are this influential in a rare vascular disease, what else might they be silently controlling in our daily health that we have yet to discover?